Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 18 February 2014 | By Alexander Gaffney, RAC,
US Food and Drug Administration (FDA) officials on Tuesday released an extensive guidance document aimed at clarifying elements of the medical device pre-submission program, now used to provide manufacturers and application sponsors with feedback and advice.
Those meetings are crucial to identifying, clarifying and mitigating any issues with a clinical trial or full medical device application, which can be delayed or derailed entirely by regulatory issues. The meetings, then, are a way for industry to identify regulatory efficiencies and for FDA to save review resources for where they are needed most.
But by virtue of the fact that the pre-submission program and its various meetings encompass nearly every conceivable problem and type of interaction, FDA's guidance on its topic isn't typical. Whereas most guidance documents weigh in at around 10-20 pages, FDA's Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with FDA Staffweighs in at a massive 53 pages.
Within the guidance is information on when to submit information to FDA, what information to submit, how FDA provides feedback, the logistics of meeting with FDA and which meeting types to request.
Also included in the guidance are various appendixes clarifying various issues associated with specific types of applications, including Investigational Device Exemptions (IDE), 510(k)s, premarket approval applications (PMA), humanitarian device exemptions (HDE) and In Vitro Diagnostic (IVD) applications. Also included are details about pre-submission meetings for non-significant risk (NSR) devices, which are exempt from FDA's usual premarket approval standards.
The pre-submission program was formerly known as the Pre-IDE program, and FDA wrote in its accompanying Federal Register notice that the new guidance is intended to provide industry with updated expectations that reflect the "broader scope" of the program, including new medical device co-regulated by the Centers for Devices and Radiological Health (CDRH) and Biologics Evaluation and Research (CBER).
The draft version of the guidance was released in July 2012.
Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with FDA Staff
Federal Register Notice
Tags: Pre-Submission program
Regulatory Focus newsletters
All the biggest regulatory news and happenings.